{
  "docId": "019de076-b3a4-71cc-8183-985590ab9557",
  "docSlug": "2fc842fd1dad3dbfa44767764fb3543f",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 21 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 21,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a before-after-bridge style framing to connect pain points to product benefits.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b3a4-71cc-8183-985590ab9557/5",
  "deckHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557",
  "deckJsonHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json",
  "deckAnchorHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.39
      },
      "kind": "list",
      "text": "Next-generation cell therapy programs have become increasingly complex requiring multiple edits vs Flow Electroporation® technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "014cf9bb-decf-415a-9dee-d0d5026b61fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster vs ExPERT™ platform provides industry leading transfection efficiency & cell viability at high scale in 30 minutes or less",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4db2db62-4dbd-4b0c-9884-0efcccb4aacd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.26
      },
      "kind": "list",
      "text": "Lack of industry standard for process design causes development to be costly and inconsistent across manufacturing runs vs MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a81fe808-b872-43fd-a0c9-1197816866ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.52
      },
      "kind": "list",
      "text": "Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) vs FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory review",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6ebc3ea-6298-4017-a9d1-3125d0a4156f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ExPERT™ Platform Addresses Industry Challenges",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31bf1da2-9dcb-4be5-9d59-99bbc32b5913",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "title",
      "text": "Challenges",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a970da5b-70af-4314-b3e4-9349f7cff18c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.47,
        "y": 0.18
      },
      "kind": "title",
      "text": "MaxCyte's Solutions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db217d8f-1a90-4e27-933d-db5bffecc62c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "99723d60-1c3c-418e-8d7e-b3710492bfe0",
      "evidence": "list/comparison: Next-generation cell therapy programs have become increasingly complex requiring multiple edits vs Flow Electroporation technology facilitates multiplex and sequential engineering without the payload",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "e69e5271-fd1f-4af5-a151-31b2d7649da3",
      "evidence": "Maps specific industry challenges to corresponding product solutions.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "5e779fca-b3fc-47b1-84f6-7724896679e4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The problem statement is presented on page 5.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "77b85c35-fbe8-46b0-acc0-1343f8c27f84",
      "evidence": "The problem statement and solution sections imply the cost of inaction.",
      "position": 0,
      "objective": "What are the consequences of not addressing cell engineering challenges?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}